# A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes

> **NCT00312130** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 20 (—)

## Conditions studied

- Pre-diabetes

## Interventions

- **DRUG:** Vildagliptin

## Key facts

- **NCT ID:** NCT00312130
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 20 (—)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00312130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00312130, "A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00312130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*